Floatz logo

90 assets in Ovarian Serous Adenocarcinoma

Therapeutic assets addressing Ovarian Serous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
sc0191
Ovarian Serous Adenocarcinoma
Biocity Biopharmaceutics Co., Ltd.P1/2CCC (48)
Tocilizumab
Ovarian Serous Adenocarcinoma
Regeneron PharmaceuticalsP1/2CCC (48)
Ubamatamab
Ovarian Serous Adenocarcinoma
Regeneron PharmaceuticalsP1/2CCC (48)
Fludarabine
Ovarian Serous Adenocarcinoma
TCR2 TherapeuticsP1/2CC (47)
Gavo-Cel
Ovarian Serous Adenocarcinoma
TCR2 TherapeuticsP1/2CC (47)
Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide
Ovarian Serous Adenocarcinoma
GenmabP1/2CC (47)
Modi-1 Moditope
Ovarian Serous Adenocarcinoma
Scancell LtdP1/2CC (47)
Pasifolate Exatecan
Ovarian Serous Adenocarcinoma
Elucida OncologyP1/2CC (47)
tc-510
Ovarian Serous Adenocarcinoma
TCR2 TherapeuticsP1/2CC (47)
Tolinapant
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P1/2CC (47)
Vls-1488
Ovarian Serous Adenocarcinoma
Volastra Therapeutics, Inc.P1/2CC (47)
azd8421
Ovarian Serous Adenocarcinoma
AstraZenecaP1/2CC (45)
Camizestrant
Ovarian Serous Adenocarcinoma
AstraZenecaP1/2CC (45)
Ribociclib
Ovarian Serous Adenocarcinoma
AstraZenecaP1/2CC (45)
ai-061
Ovarian Serous Adenocarcinoma
OncoC4, Inc.P1CC (43)
Atx-295
Ovarian Serous Adenocarcinoma
Accent TherapeuticsP1CC (43)
Azirkitug
Ovarian Serous Adenocarcinoma
AbbVieP1CC (43)
Berzosertib
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Bet Bromodomain Inhibitor Zen-3694
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Bms-986463
Ovarian Serous Adenocarcinoma
Bristol-Myers SquibbP1CC (43)
Budigalimab
Ovarian Serous Adenocarcinoma
AbbVieP1CC (43)
Capivasertib
Ovarian Serous Adenocarcinoma
M.D. Anderson Cancer CenterP1CC (43)
Elimusertib
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
ide034
Ovarian Serous Adenocarcinoma
IDEAYA BiosciencesP1CC (43)
Ipatasertib
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Ipn 60090
Ovarian Serous Adenocarcinoma
M.D. Anderson Cancer CenterP1CC (43)
lyl797
Ovarian Serous Adenocarcinoma
Lyell Immunopharma, Inc.P1CC (43)
Navitoclax
Ovarian Serous Adenocarcinoma
Sunnybrook Health Sciences CentreP1CC (43)
Re-Stimulated Tumor-Infiltrating Lymphocytes
Ovarian Serous Adenocarcinoma
University Health Network, TorontoP1CC (43)
Sovilnesib
Ovarian Serous Adenocarcinoma
Volastra Therapeutics, Inc.P1CC (43)
Telisotuzumab Adizutecan
Ovarian Serous Adenocarcinoma
AbbVieP1CC (43)
Trastuzumab Deruxtecan
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Tuvusertib
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Vcn-01
Ovarian Serous Adenocarcinoma
University of PennsylvaniaP1CC (43)
Vistusertib
Ovarian Serous Adenocarcinoma
M.D. Anderson Cancer CenterP1CC (43)
zm008
Ovarian Serous Adenocarcinoma
Zumutor Biologics Inc.P1CC (43)
Adavosertib
Ovarian Serous Adenocarcinoma
M.D. Anderson Cancer CenterEarly P1C (39)
Hucart-Meso Cells
Ovarian Serous Adenocarcinoma
University of PennsylvaniaP1C (37)
Avb-001
Ovarian Serous Adenocarcinoma
Avenge Bio, IncP1/2NR ()
Showing 51 to 90 of 90 assets
PreviousPage 2 of 2Next